drugset / Trial / NCT02270307

MSC and Cyclophosphamide for Acute Graft-Versus-Host Disease (aGVHD) Prophylaxis

NCT02270307

Phase 2/3 Unknown 40 enrolled National Research Center for Hematology, Russia
NaSingle-groupOpen-labelPrevention

Summary

Evaluating the effectiveness of the new protocol which replace the standard immunosuppressive therapy with use of MSCs and CY in patients at high risk of relapse.

Timeline

Start
2014-01
Primary completion
2016-01
Completion
2016-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Cyclophosphamide Other / unclassified 50 mg/kg
Subject mesenchymal stem cells Cell therapy 1e+06 cells/kg